Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mobic · 2 trials · 1 indication
Bioequivalence based on Cmax
Bioequivalence based on AUC0-inf
Bioequivalence based on AUC0-t
| Arm | Type | Description |
|---|---|---|
| Meloxicam | EXPERIMENTAL | Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period |
| Mobic® | ACTIVE_COMPARATOR | Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period |
| Name | Type | Description |
|---|---|---|
| Meloxicam 15 mg Tablets | DRUG | 1 x 15 mg, single-dose fasting |
| Mobic® 15 mg Tablets | DRUG | 1 x 15 mg, single-dose fasting |
Inclusion Criteria: * Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non tobacco user for at least 90 days prior to pre-study medical). * Body mass Index (BMI = weight/height²) greater than or equal to 18.5 kg/m² and less than or equal to 29.9 kg/m². * Availability of...
Mobic is a small molecule medicine developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. It is also known as Mobic 15 mg Tablets. The clinical program for Mobic has been studied in Phase 1 trials, and the specific therapeutic indication has not been disclosed.
Mobic is developed by Teva Pharmaceutical Industries Limited, a pharmaceutical company listed under the ticker TEVA. Teva is the sponsor associated with the clinical development program for Mobic and its 15 mg tablet formulation.
Mobic is in Phase 1 clinical development. Two Phase 1 trials of Mobic 15 mg tablets have been completed, and no trials are currently active. The studies enrolled a combined total of 56 participants.
Mobic has been evaluated in two completed Phase 1 trials: NCT00840879, titled Meloxicam 15 mg Tablets Under Non-Fasting Conditions, and NCT00840476, titled Meloxicam 15 mg Tablets Under Fasting Conditions. Both enrolled 28 healthy adult volunteers in Canada and were active controlled and randomized.
The two completed Phase 1 trials of Mobic examined meloxicam 15 mg tablets under fasting and non-fasting conditions. Both were randomized, active controlled studies in healthy volunteers aged 18 years and older, with 28 participants each, conducted in Canada.